Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

Summary

The study objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids.

Timeline

Start

2011-01

Primary completion

2019-11

Completion

2019-11

Outcome

Met primary endpoint

release “The phase 3 study (AB07015) evaluating oral masitinib in the treatment of severe asthma not controlled by oral steroids met its primary objective.” ab-science.com ↗

release “Phase 3 study (AB07105) evaluating oral masitinib at 6 mg/kg/d versus placebo in severe asthma uncontrolled by oral corticosteroids (OCS) met its primary endpoint.” ab-science.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Masitinib	Small molecule	6 mg/kg	Oral

Indications